Immune checkpoint blockade (ICB) antibodies block the interactions between Programmed Death-1 (PD-1) expressed on activated and “exhausted” T cells and the PD-L1 ligand expressed on cancer cells and tumor-associated immune cells in the tumor microenvironment (TME) to unleash a T cell immune attack against cancer cells (1–3). Here, CD274 is linked to cancer.